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INTRODUCTION 
 Anaesthesia has made major advances in recent years. 
Considerable efforts have been devoted to airway management by 
the anesthesiologist during the past 20 years. A large number of 
supraglottic airway devices have been introduced recently. The 
original purpose was to reduce the need for more invasive 
methods of airway management while offering a more reliable 
alternative to the facemask. The laryngeal mask airway (LMA) is 
one such innovative device designed for airway management. 
 Dr.A.I.J. Brain originally described it primarily as an 
alternative to the facemask and the endotracheal tube1. Pennat 
J.H. White P.F. (1993), described it as the missing link between 
these two devices2.   
 One of the principal aims of anaesthesia is to counter 
surgically induced stress. So the anesthesiologist should be able 
to use a method of delivering the anaesthetic that is by itself not 
stress inducing3. Since the LMA is placed directly over the 
posterior pharynx, it avoids tracheal stimulation and hence the 
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systemic and ocular stress response associated with tracheal 
intubation. 
LMA offers distinct advantages over the facemask and the 
endotracheal tube. Compared to the facemask, the LMA 
maintains a better airway, frees the hands and thereby reduces the 
fatigue of the anesthesiologist. Oxygenation during anaesthesia 
has shown to be better with the LMA compared to the facemask. 
LMA is an extremely versatile device that can be used for the 
administration of inhaled anaesthetics, as a conduit for 
ventilation during administration of anaesthesia, as a device for 
emergency ventilation. It can also be used as a tracheal intubation 
assist device2,4  and  as an emergency airway device during 
resuscitation. Now, LMA is assuming an increasingly prominent 
role in management of patients with a difficult airway. The LMA, 
as a ventilatory device /intubating conduit is placed in the ASA 
difficult airway algorithm in five places.   
Airway-related advantages of the LMA compared to the 
tracheal tube include better patient tolerance of the LMA, which 
results in a more secure artificial airway for a longer period of 
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time during emergence. Furthermore, it provides a clear airway in 
the postoperative period5,6.  
The LMA has gained widespread acceptance as general-
purpose airway and is a used in up to 30% of patients undergoing 
general anaesthesia7.Despite the popularity of LMA for airway 
maintenance during general anaesthesia, there is a still no optimal 
induction technique that guarantees good insertion conditions 
while maintaining cardiovascular stability and rapid onset of 
respiration. The most popular induction agent for LMA insertion 
continues to be Propofol as this agent obtunds oropharyngeal 
reflexes 8,9. Studies show an incidence of poor insertion 
conditions ranging from 38-60%10,11,12 with standard induction 
doses (2-3mg/kg) of Propofol however its use in doses which 
allow adequate jaw relaxation and prevent patient reaction to 
LMA insertion8,10 i.e., gagging, coughing, movements etc., 
commonly results in hypotension13,14,15,16,17,18 and prolonged 
apnoea. Although this dose of Propofol may be well tolerated by 
a fit patient, it may not be tolerated by elderly patients and in 
those patients with cardiovascular disease. 
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There have been numerous studies that looked into co-
induction techniques combining a lower dose of Propofol or 
thiopentone with other agents, including 
Benzodiazepines19,20,21,22, rapidly acting opiates11,22, 
neuromuscular agents23,24,25 and topical26 and intravenous local 
anaesthetic agents. Use of rapid onset, neuromuscular blocking 
agents such as succinylcholine, suppresses the laryngeal reflexes 
by depolarization of motor-neuron end plates. However their use 
may result in significant myalgia27and prolonged apnoea. Nimmo 
and colleagues suggested that this adverse reactions can be 
avoided by reducing the doses of suxamethonium 
substantially27..Also studies suggest that midazolam, a short 
acting benzodiazepine, aids LMA insertion through its centrally 
acting muscle relaxant properties. 
A prospective randomized controlled study was constructed 
to compare the usefulness of midazolam and mini dose succinyl 
choline to aid LMA insertion during propofol anesthesia, in 
patients coming for elective short general surgery procedures. 
The study was conducted in Department of Anesthesiology, 
Madras Medical College. 
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LARYNGEAL MASK AIRWAY 
Dr Archie Brain invented the laryngeal mask airway at 
London hospital, White Chapel in 1981. LMA has ribbed orifices 
at the patient end that is continuous with the large tube. The ribs 
protect against airway obstruction by the epiglottis. Mask is 
connected to the lumen at an angle of 30. The mask is equipped 
with an inflatable cuff intended for airtight seal around the 
larynx. It has a pilot balloon with an inflatable valve, inflating 
tube which aids the inflation of the cuff. The black line runs 
along the whole length of the tube up to the mask and serves to 
indicate the correct position of the mask in the airway. At the 
machine end of the tube there is a standard 15mm connector. 
              LMA is constructed from silicone rubber,(avoiding latex 
and thereby latex allergy), and also has an advantage that it can 
be autoclaved and reused. LMAs are available in the following 
sizes,1,1.5,2,2.5,3,4,5,6 .Volume of air injected to inflate the cuff 
ranges from 4ml for 1 size LMA to 40ml for 6 size LMA. The 
volume to be injected is written on the LMA itself.  
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TYPES OF LARYNGEAL MASK AIRWAY 
LARYNGEAL MASK AIRWAY UNIQUE 
The cuff of this LMA is made up of PVC. It is a disposable 
LMA used in emergency situations. 
FLEXOMETALLIC LARYNGEAL MASK AIRWAY 
It consists of a wire reinforced tube connected to a standard 
laryngeal Mask. It can be used for head and neck surgeries. 
INTUBATING OR FASTRACH LARYNGEAL MASK AIRWAY 
It is used for difficult intubations where we can intubate 
with 8mm ID endotracheal tube through the laryngeal mask 
airway. 
LARYNGEAL MASK AIRWAY – PROSEAL 
It is designed for use in positive pressure ventilation at high airway 
pressures. The mask has a cuff which seals around laryngeal  opening and 
a rear cuff that acts to increase the seal. A drain tube is present within 
the mask. 
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CHECKING OF LMA  
 The device can be re-used after autoclaving up to 40 times 
according to manufactures’ recommendation. LMA must be 
checked before each use. The exterior of the tube should be 
checked for cracks. The interior of the tube should be checked for 
any foreign body. The cuff of the LMA should be tested by filling 
with air, 50% more than the recommended volume for any leaks. 
LMA INSERTION – STANDARD TECHNIQUE 
 The cuff must be fully and correctly deflated before 
placement. This imparts rigidity to the tip of the cuff. The 
deflated cuff should be free from wrinkles and its rim should face 
away from the masks aperture. 
 A lubricant, usually 2% lignocaine jelly is applied to the 
posterior surface of the cuff just before placement. This prevents 
the cuff tip from rolling over on contact with the palate. 
Lubricant applied on the anterior surface may block the aperture 
or be inhaled causing airway obstruction, coughing and 
laryngospasm. After adequate general anesthesia or topical 
anesthesia (or complete muscle relaxation have been achieved,) 
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patients neck is flexed and head extended by pushing the head 
with the non dominant hand (sniffing position). Open the mouth 
with the 3rd finger of the dominant hand. LMA is held between 
the index finger and thumb of the dominant hand as close to the 
junction of the tube and the mask. The aperture of the mask faces 
the chin. The tip of the cuff is placed against the inner surface of 
the patients upper incisor teeth. It is important that at this point 
the tube should be parallel rather than vertical. The mask is then 
pressed upwards against the hard palate and advanced into the 
oral cavity maintaining upward pressure. When the device is 
advanced, it is essential that the tip of the LMA should not roll 
over. When the mask is fully advanced, resistance will be felt. 
The tube is then held in the non dominant hand and the index 
finger is withdrawn. Appropriate volume of air should be used to 
inflate the cuff. The tube will move slightly out of the mouth 
when the cuff is inflated. This confirms the position of the mask. 
Then the LMA is connected to the breathing circuit and adequacy 
of ventilation should be assessed. A bite block inserted into the 
mouth. 
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PARTIAL INFLATION TECHNIQUE 
 The cuff of the LMA is partially inflated before insertion. 
In this technique the incidence of down folding and trapping of 
epiglottis is reduced. 
180 DEGREE TECHNIQUE 
 In this technique LMA is inserted with the laryngeal 
aperture pointing cephalad and rotate it 180 degrees. This method 
is useful in paediatric patients.  
ANATOMICAL POSITION OF LARYNGEAL MASK AIRWAY 
When the LMA is placed correctly its distal part occupies 
the hypopharynx and the tip rests on upper oesophageal sphincter 
at the level of sixth cervical vertebra. Thus the distal part of the 
LMA lies posteriorly to the thyroid cartilage and the tip of the 
LMA lies at the level of cricoid cartilage. The sides of the mask 
face into the pyriform fossae. The proximal edge of the mask is 
under the base of the tongue below the level of tonsils. When the 
tube is fixed properly the curve of the tube should follow that of 
the palate. Epiglottis is prevented by median aperture bars from 
obstructing the airway. The mean distance from the grill of the 
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mask to the vocal cord is 3.1cms in women and 3.6cms in men. 
When the cuff of the mask is being inflated the thyroid, 
arytenoids and cricoid cartilages are pushed anteriorly and tissues 
overlying the larynx bulge out slightly. 
REMOVAL OF LARYNGEAL MASK AIRWAY 
 LMA should be removed only when the patient responds to 
oral commands and their protective airway reflexes have returned 
to normal. LMA should not be removed in lighter planes as this 
may cause coughing and laryngospasm. 
ADVANTAGES OF THE LARYNGEAL MASK AIRWAY 
Easy placement in trained hands. 
Shorter time for insertion 
Minimal hemodynamic changes during insertion and removal 
Minimal stimulation if left insitu until protective reflexes have 
returned 
Minimal increase in intra ocular and intra cranial pressures 
Reduced incidence of sore throat. 
 11
DISADVANTAGES OF LARYNGEAL MASK AIRWAY 
Gastric inflation can occur and risk of aspiration not eliminated 
Obstruction by epiglottis 
Laryngospasm during lighter plane. 
INDICATIONS OF LARYNGEAL MASK AIRWAY 
Emergency airway management in failed intubation 
Surface surgeries of trunk and extremities 
Minor urological and gynaecological procedures 
Useful in patients where maintenance of airway is difficult such 
as edentulous patients, facial injury, burns. 
Can be used for diagnostic bronchoscopy, laryngoscopy 
For emergency securing airway during CPR 
CONTRA INDICATIONS 
Patients with full stomach 
Abnormal airway anatomy like tumour   
Restricted mouth opening.  
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PHARMACOLOGY 
The main drugs used in our study are Propofol, Midazolam 
and Succinyl choline. The pharmacology of the drugs are 
discussed below. 
PROPOFOL    
Propofol (ICI 35868, Diprivan Propovan) is a recent 
intravenous anaesthetic to be introduced into the clinical practice 
work in 1970s on substituted derivatives of phenol with hypnotic 
properties resulted in the development of 2,6, di iso 
propylphenol. The first clinical trial by Key and Rolly reported in 
1977 confirmed the potential of propofol as an anesthetic 
induction agent. 
Physicochemical Properties 
 Propofol is a hindered phenol, which is chemically 
dissimilar to any other compounds used in anaesthesia. 
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It is 2,6, Di – isopropylphenol 
 
 
 
 
Propofol is oil at room temperature and it is insoluble in 
water and therefore it was initially prepared with cremophor EL. 
Because of anaphylactoid reaction associated with cremophor EL 
in this early formulation of the Propofol the drug was 
reformulated in an emulsion. 
The present formulation consist of 
• 1% (wt/Vol) Propofol 
• 10% (w/v) soyabean oil 
• 2.25% (w/v) glycerol 
• 1.2% (w/v) purified egg phosphatide 
H3C OH 
H3C 
CH HC 
CH3 
CH3 
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The pH is 6- 8.5 (7) and the PKa of the drug in water is 11. 
The solution appears as lightly viscous, milky white substance. It 
is made isotonic with glycerol and is sealed under nitrogen. 
Propofol is available as a 1% solution in 10 ml, 20 ml, and 50ml 
vials and 10 ml ampoules. It is stable at room temperature and is 
not light sensitive. 
The precautions which apply to intravenous fat emulsions 
must be taken with Propofol, that is, it should be stored below 
25oC but must not be frozen. Ampoules should be shaken before 
use. Filters should not be used during administration of emulsion. 
It should not be mixed before administration with other 
therapeutic agents or infusion fluids. It can be administered 
through a Y – piece close to the injection site into crystalloid 
infusion such as dextrose or normal saline. 
PHARMACOKINETICS 41,42 
Propofol is rapidly metabolized in the liver by conjugation 
to glucuronide and sulfate to produce water soluble (2,6 di-
isopropyl 1,4 quinol and other) compounds, which are excreted 
by the kidneys. Less than 1% Propofol is excreted unchanged is 
urine and only 2% excreted in faeces. The metabolites of 
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Propofol are thought not to be active. Because clearance of 
Propofol exceeds hepatic blood flow, extra hepatic metabolism or 
extrarenal elimination has been suggested. Extra hepatic 
metabolism has been confirmed during the anhepatic phase of 
patients receiving a transplanted liver. 
Women have a higher volume of distribution and higher 
clearance rates. The elderly have decreased clearance rates but 
smaller central compartment volume. Children have a large 
central compartment volume and a more rapid clearance. Hepatic 
disease appears to result in a larger steady state and central 
compartment volumes. Clearance is unchanged but the 
elimination half – life is slightly prolonged. 
PHARMACODYNAMICS43 
Effect on Central Nervous system (CNS): Propofol is primarily a 
hypnotic. The exact mechanism of action has not yet been fully 
elucidated, however, evidence suggest that it acts by enhancing the 
function of GABA activated chloride channel. Though Propofol has no 
analgesic property as such, propofol does not produce antanalgesia and 
clearly superior to thiopentone in this respect. At subhypnotic doses, 
Propofol will provide sedation and amnesia. The effects of Propofol on 
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EEG are the initial increase in α rhythm followed by shift to δ and θ 
frequency.  High infusion rates produce burst suppression. 
 Several recent studies have shown a direct anticonvulsant effect of 
Propofol, which is dose dependent. Propofol does not alter brain stem 
auditory evoked potential. Propofol will decrease the intracranial pressure 
(ICP) in patients with either normal or elevated ICP. It also reduces 
cerebral perfusion pressure. Normal cerebral reactivity to CO2 and 
autoregulation are maintained during Propofol.  Propofol reduces the 
CMRO2. 
Effect on Cardiovascular System (CVS): The most prominent effect of 
Propofol on CVS is a decrease in arterial blood pressure during induction 
of anaesthesia. It produces 25% to 40% (Mean 30%) reduction of systolic 
blood pressure. Similar changes are seen in mean and diastolic pressure. 
The decrease in arterial pressure is associated with a decrease in cardiac 
output / cardiac index (about 15%), stroke volume index (about 20%) and 
systemic vascular resistance (15 to 20%). 
 But reduction in arterial pressure is largely due to the decrease in 
systemic vascular resistance. The hypotensive effect of Propofol is more 
marked when the drug is given by intermittent administration even for 
short procedures. During the maintenance of anaesthesia with a Propofol 
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infusion, systolic pressure remains between 20% and 30% below 
preinduction levels. 
 The decrease in systemic pressure following induction dose of 
Propofol appears to be due to both vasodilatation and myocardial 
depression. Both the myocardial depressant effect and vasodilatation 
appear to be dose and plasma concentration dependent. The vasodilatory 
action is due to a direct effect on intracellular smooth muscle Ca++ 
mobilization. Heart rate does not change significantly after an induction 
dose of Propofol. It has been suggested that Propofol either resets or 
inhibits the baroreflex, thus reducing the tachycardiac response to 
hypotension. An infusion of Propofol results in a significant reduction in 
both myocardial blood flow and myocardial oxygen consumption. 
Effect on Respiratory System (RS) :The first disturbance seen after 
administration of a bolus dose of  Propofol is a profound fall in tidal 
volume leading to apnoea44. The incidence and duration of apnoea are 
dependent on dose, premedication and speed of injection. The apnoea 
occurring with Propofol however may be prolonged to more than 30 
seconds. The incidence of prolonged apnoea (longer than 30 seconds) is 
further increased by addition of an opiate either as a premedication or just 
prior to induction. A maintenance infusion of Propofol results in a 40% 
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decrease in tidal volume and a 20% increase in respiratory rate. The 
ventilatory response to carbon dioxide & hypoxia are depressed. 
Other Effects   
• Propofol does not trigger malignant hyperpyrexia and is probably 
the anaesthetic of choice in patients with this condition. 
• Propofol also possess significant antiemetic property at low 
(subhypnotic) doses. Propofol as an infusion of 1mg/kg/hr 
provided excellent antiemetic action following chemotherapy 
Side Effects  
1. Pain on injection – its reduced by using a large vein, avoiding the 
vein on the dorsum of the hand, adding Lignocaine to the Propofol 
infusion. 
2. Excitatory effects like myoclonus i.e. muscle twitching, tremors; 
hiccup may occur following Propofol administration. 
3. Apnoea following the Propofol as an induction agent is common, 
which lasts for 30s or for longer duration. The addition of an opiate 
increases the incidence of apnoea especially prolonged apnoea. 
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4. The most significant side effect on induction is the decrease in 
systemic blood pressure. Perhaps slow administration and lower 
dose in adequately pre hydrated patients may attenuate the decrease 
in arterial blood pressure. 
Contraindications 
• As Propofol produces fall in arterial blood pressure it cannot 
be used in patients in shock and hypotension 
• Should not be used in patients with history of 
hypersensitivity to Propofol 
Clinical Uses 
• Induction and maintenance of anaesthesia – Propofol is suitable 
for both the induction and maintenance of anaesthesia. Propofol 
because of its pharmacokinetics, provides a rapid recovery and is 
thus superior to barbiturates. For maintenance of anaesthesia, 
Propofol can be given as intermittent boluses or as a continuous 
infusion. 
• Propofol for outpatient surgery – Propofol when used for 
induction of anaesthesia in shorter procedures, results in a 
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significantly quicker recovery and an earlier return of psychomotor 
function. The incidence of nausea and vomiting are markedly less 
when Propofol is used for induction. 
• Recovery from anaesthesia with Propofol is sufficient to allow the 
patients to be sent home on the same day, after the surgery is 
performed. walking ability and correct balance also returns more 
quickly after propofol anaesthesia 
• Propofol for Total intravenous anaesthesia – Propofol produces 
satisfactory conditions for surgery with no unwanted effects during 
maintenance. 
• Propofol for sedation – Propofol by continuous infusion45 provides 
a readily titratable level of sedation and rapid recovery once the 
infusion is terminated, irrespective of the duration of the infusion. 
• Propofol can be used for sedation as an adjunct to regional 
anaesthesia. It can be used as an infusion or in the form of 
intermittent doses. 
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Doses of Propofol 
Induction of General anaesthesia 1 – 2.5mg/kg IV (Dose reduced 
with increasing age) 
Maintenance of General Anaesthesia 50 – 150 µg/kg/min I.V. 
combined with N2O or opiate 
Sedation 25 – 75 µg/kg/min I.V. 
 
SUCCINYL CHOLINE 
History: The first report on the administration of Succinylcholine  for 
performing endotracheal intubation  in multiple cases in the ED was 
published by Thompson et al   
1906 – Reid hunt described its pharmacological actions ;   
1949 – Bovet et al described its neuromuscular blocking actions; 
1951 – Thesleff first used the drug in man at Stockholm. 
Chemistry: Succinyl choline is a synthetic muscle relaxant, a quaternary 
amine ester, consisting of two molecules of acetylcholine joined together 
through their acetyl groups. 
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MOLECULAR STURTURE OF SUCCINYL CHOLINE 
   O 
   ⎮⎮ 
   Co CH2 CH2 N+ (CH3) 3 
   ⎮ 
(CH2) 2 
⎮  
   Co CH2 CH2 N+ (CH3) 3 
⎮⎮ 
O 
Presentation: As a solution, it is available in 10ml vials containing 
50mg/ml and in vials containing 100mg powder form. Storage: 40C. 
Spontaneous hydrolysis occurs in warm/alkaline conditions. 
Routes of administration: Intravenous/ Intramuscular 
Dose: ED95   - 0.51 – 0.63 mg/kg 
Intubation dose - Adults:  1-1.5 mg/kg IV bolus 
     Children:  2-2.5 mg/kg 
 Onset of action - 30 to 60 sec. 
 Duration of action - 4 to 10 min. 
 23
Mechanism of action: succinylcholine attaches to each of the alpha 
subunits of the nicotinic cholinergic receptor and mimics the action of 
acetyl choline thus depolarizing the post junctional membrane. Here, the 
hydrolysis is slow resulting in sustained depolarization (opening) of the 
receptor ion channels. Neuromuscular blockade develops because a 
depolarized post junctional membrane cannot respond to subsequent 
release of acetyl choline (Depolarizing Blockade). It is otherwise called 
as Phase I Blockade, which is characterized by  
a) Absence of fade with TOF or tetanic stimulation. 
b) Absence of post tetanic facilitation 
c) Increased blockade with anticholinesterase drug such as 
Neostigmine and Edrophonium 
 The pre synaptic receptors are involved in the production of 
fasciculations. 
Phase II Blockade :( non-depolarizing/dual) 
• Single large dose of succinyl choline (> 2mg /kg IV) 
• Repeated small doses of succinyl choline  
• Prolonged continuous infusion  
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may result in post junctional membranes that do not respond normally to 
Acetyl choline even when the post junctional membranes have become 
repolarized (desensitization blockade). Mechanism for this blockade is 
unknown. Phase II blockade has non-depolarizing characteristics such as 
a) fade with TOF or tetanic stimulation 
b) post tetanic facilitation 
c) antagonism of blockade with anticholinesterase agents 
Metabolism: Succinyl choline is rapidly hydrolyzed by plasma 
cholinesterase to choline and succinyl monocholine. 
Succinyl choline 
Plasma cholinesterase (rapid) 
Succinyl monocholine + choline 
     Plasma cholinesterase (slow) 
   Succinic acid + choline 
Dibucaine number and pseudo cholinesterase activity 
Dibucaine, a local anaesthetic, inhibits the normal pseudo 
cholinesterase activity by about 80% and the homozygous atypical 
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enzyme by about 20%. The heterozygous enzyme is characterized by an 
intermediate 40 – 60% inhibition. The percentage inhibition of 
cholinesterase by 10-5 molar solution of Dibucaine is termed the 
Dibucaine number. The percentage of inhibition of cholinesterase by 5 x 
10-5 molar sodium fluoride is termed as Fluoride number. Dibucaine 
number indicates the genetic make up of an individual with respect to 
pseudo cholinesterase. It does not measure the concentration of the 
enzyme in the plasma nor does it indicate the efficiency of the enzyme in 
hydrolyzing the substrate such as succinyl choline. The activity of the 
enzyme refers to the number of substrate molecules in mmols hydrolyzed 
per unit of time. Pseudo cholinesterase activity is certainly markedly 
influenced by the genotype, but is also dependent on the concentration of 
the enzyme in the plasma. Of the population 94% are normal Eu Eu 
genotypes with normal enzyme activity and a DN of 75 – 85. 
Three abnormal genes exist: 
1. Ea (atypical) homozygotes comprise 0.03% of the population;  
2. Ef (fluoride resistant) homozygotes comprise 0.0003% of the 
population; 
3. Es (silent) homozygotes comprise 0.001% of the population. 
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 Normal serum cholinesterase level about 80 u/ml 
Heterozygous atypical enzyme: occurs in 1/50 patients resulting in a 
slightly prolonged block (20 – 30 mins), whereas Homozygous atypical 
enzyme: occurs in 1/3000 patients resulting in a very long blockade (6 – 
8 hrs). 
Abnormalities of suxamethonium metabolism: 
1. Abnormal plasma cholinesterase (inherited):  
i. Atypical cholinesterase – Mendelian recessive Ea Ea 
homozygotes (1/3000 population) have 1 – 2 hr apnoea, during 
which phase 2 block develops (DN 16 – 25). Heterozygotes 
(1/25 population) have little or no disturbance (DN 50 – 65), 
with apnoea upto 10 mins. 
ii. Fluoride resistant – homozygotes have 1 h apnoea, with phase II 
block (DN 16 – 25). Heterozygotes have 10 min apnoea (DN 50 
– 65). 
iii. Silent gene  
 27
2.  Plasma cholinesterase deficiency  
Factors lowering pseudo cholinesterase concentration are 
i. liver disease 
ii. pregnancy 
iii. burns 
iv. drugs – OCPs, MAO inhibitors, echothiophate, cytotoxic drugs, 
anticholinesterases, tetrahydroaminacrine, metoclopramide, 
hexafluorenium,  bambuterol,  Esmolol. 
v. neoplastic disease 
Adverse Effects 
1. Prolonged apnoea: As discussed above, patients with abnormal 
pseudocholinesterase or deficient enzyme will experience markedly 
prolonged paralysis (range: 20 mins – 8 hrs.) 
2. Cardiovascular effects : Bradycardia: It is the most frequently 
encountered change in rate. It is usually seen after the administration of 
relatively large single dose injections. The higher incidence of 
bradycardia after a second dose of succinyl choline suggests that the 
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hydrolysis product of succinyl choline may sensitize the heart to a 
subsequent dose. Succinyl choline stimulates all cholinergic autonomic 
receptors – nicotinic receptors on both sympathetic and parasympathetic 
ganglia, and muscarinic receptors in the sinus node of the heart. In low 
doses, both negative inotropic and chronotropic responses may occur and 
in large doses, these effects may become positive. One prominent clinical 
manifestation of this generalized autonomic stimulation is the 
development of cardiac arrhythmias, such as nodal bradycardia and 
ventricular ectopics, ventricular fibrillation. A high vagal background 
may predispose to asystole when a single dose of succinyl choline is 
administered. 
3. Fasciculations: Appear within a few seconds of succinyl choline 
administration and are most often evident in young muscular adults. They 
are uncommon in children and intensity is less in the elderly. Muscle 
fasciculations can increase serum potassium level by 0.5-1.0 meq/L and 
produce arrhythmias. The mechanism is most likely a depolarization of 
nerve terminals through succinyl choline’s action at the presynaptic 
receptors. This produces anti-dromic firing in the nerve, with the 
propagation of the action potential to all branches supplying a motor unit. 
The extension of fasciculations in the body is dependent on the arterial 
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blood distribution. Muscles close to the aorta and receiving the drug first 
are early affected.  
4.  Muscle pains: There is  increased incidence of post-operative 
myalgia, 24 – 48 hrs after succinyl choline, more frequently following 
minor surgery, especially in women and in ambulatory. Pregnancy and 
extremes of age seems to be protected. Pain is secondary to damage 
produced in muscle by the unsynchronized contractions of adjacent 
muscle fibers just before the onset of paralysis. The finding of 
myoglobinemia and increased serum Creatine kinase following 
succinylcholine  administration substantiates this. The efficacy of non-
depolarizing pre-treatment is controversial.  
5. Hyperkalemia  :Potassium is released from muscles following 
suxamethonium injection, causing a rise of serum potassium of 0.2 – 0.4 
mmols/L. A life threatening elevation of potassium is possible in patients 
with  
a) Massive trauma, closed head injury 
b) Muscular dystrophy, neuropathies, denervation, stroke 
c) Third degree Burns 
d) UMN/ LMN Lesions 
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e) Tetanus 
f) Spinal cord injuries 
g) Congenital cerebral palsy 
h) Wasting secondary to chronic arterial insufficiency 
i) Prolonged total body immobilization 
j) Severe intra-abdominal injury 
In denervation, the extra-junctional receptors allow succinyl choline to 
effect widespread depolarization and extensive potassium release. 
6. Malignant Hyperpyrexia: Suxamethonium is a potent triggering 
agent in patients susceptible to malignant hyperthermia, together with 
potent inhalation agents. 
7.  Increased Intra Gastric Pressure : Increases to >20 mmHg due to 
severe muscle fasciculations. However, it causes a greater rise in lower 
esophageal sphincter tone, and hence it does not appear to increase the 
risk of aspiration unless the LES is incompetent, such as in pregnancy, 
hiatus hernia and obesity. 
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9.  Increased Intra Ocular Pressure: Suxamethonium 1 mg/kg raises 
the pressure by 7mm Hg partly as a result of tonic contraction of the 
extra-ocular muscles with return of normal pressure in 10 min.  
10.  Increased intracranial pressure: A mean increase of 5 mm Hg over 
the baseline is observed. This may have serious consequences with intra-
cranial compliance is limited. 
MIDAZOLAM 
Midazolam, an imidazobenzodiazepine derivative, has a molecular 
weight of 362. It has a fused imidazole ring which  accounts for its 
basicity, stability of the aqueous solution and rapid metabolism. The drug 
was synthesized in 1976 by Fryer and Walser. 
The pka of midazolam is 6.15 which permits preparation of 
watersoluble salts. The parenteral preparation of  the midazolam used in 
clinical practice is buffered to an acidic pH (3.5) in acidic aqueous media, 
midazolam is water soluble thereby allowing the parenteral formulation 
to exclude lipoidal substitutions like propylene glycol. As such 
midazolam does not cause local irritation after IM or IV use. At 
physiologic pH, midazolam becomes highly lipophilic and is one of the 
most lipid soluble of the benzodiazepines. The high lipophilicity has a 
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number of clinical consequences including rapid absorption of the drug 
from the GIT and rapid entry into brain tissue after IV administration. 
PHARMACOKINETICS 
 Midazolam is bound extensively to the plasmaproteins in the range 
of 96-97%. The unique chemical structure of midazolam confers number 
of physiochemical properties that distinguish it from other 
benzodiazepine in terms of pharmacologic and pharmacokinetic 
characteristics. 
 Metabolism involves hydroxylation by hepatic microsomal 
oxidative mechanism. The fused imidazole ring is oxidized very rapidly 
by the liver.The principal metabolite is 1-hydroxy midazolam and smaller 
amounts of 4-hydroxymidazolam  and 1,4 dihydroxymidazolam which 
are excreted in urine as glucuronide conjugates. 
 The high lipophilicity of midazolam at physiologic PH results in 
very rapid onset after IV administration. The volume of distribution is 1-
2.5 lts/kg. Half life is 1-4 hrs. The volume of distribution increases 
greatly in obese patients because of the greatly enhanced 
distribution of midazolam into peripheral  adipose tissues. 
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PHARMACODYNAMICS 
 Midazolam has the anxiolytic, hypnotic, anti convulsant, 
muscle relaxant and anterograde amnesic effects characteristic of 
benzodiazepines. It exerts its anxiolytic effect by increasing 
glycine inhibitory transmitter. The hypnotic effect is related to 
GABA accumulation .Anti convulsant activity is the enhanced 
action of GABA on the motor circuits of brain. It also exhibits 
muscle relaxant effect mediated via glycine receptors in spinal 
cord. Midazolam reduces cerebral metabolic rate for O2 and cerebral 
blood flow protecting against cerebral hypoxia in patients with raised 
ICP. Midazolam produces dose dependant respiratory depression and is 
more likely in patients premedicated with opiods. It produces significant 
reduction in BP, systolic 5% and diastolic 10%  and increase in heart rate 
by 18%. A decrease in SVR ,venodilation and a transient change in portal 
bloodflow combine to reduce the cardiac filling. It also decreases 
myocardial contractility by direct action. A reduction in BP activates 
baroreceptors and increase the heart rate. 
ADVERSE EFFECTS : are hiccups 5.6%, coughing 1.5% and nausea 
vomiting 3%. The behavioural and electrophysiological effects of 
midazolam are antagonized by benzodiazepine antagonist flumazenil. 
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USES :  
                It is used as an induction agent in a dose of 0.1 to 0.4mg/kg. 
Induction dose can be reduced in patients premedicated with opiods and 
in elderly pts. 
   It is a useful hypnotic, amnestic  during maintenance of 
anesthesia along with fentanyl and nitrous oxide 66%. 
   It is used as premedicant  due to its anxiolytic and hypnotic 
properties. 
   It is a useful intravenous adjuvant for local and regional 
anesthesia for a variety of  therapeutic and diagnostic procedures. 
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AIM OF THE STUDY 
     The aim of the study is to observe the usefulness of 
Midazolam and mini-dose of Succinyl choline to facilitate the 
insertion of laryngeal mask airway during Propofol anesthesia in 
elective general surgery patients based on the following 
parameters. 
• Conditions during insertion of laryngeal mask airway such 
as jaw relaxation, ease of insertion, number of attempts for 
insertion, airway trauma and total dose of Propofol. 
• Patient’s response to insertion of laryngeal mark airway 
such as gagging, coughing, head and limb movements, 
laryngospasm, etc. 
• Hemodynamic parameters like mean arterial pressure, heart rate 
and oxygen saturation. 
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REVIEW OF LITERATURE 
 Tracheal intubation is performed routinely during general 
anaesthesia in patients undergoing surgery to secure a clear airway, to 
allow good surgical access and to facilitate ventilation of lungs for better 
control of PaCO2 and PO2. However intubation is associated with 
tachycardia, hypertension and an increase intraocular pressure. Various 
unsuccessful attempts were tried to attenuate the response upto this date. 
 The laryngeal mask airway was invented and developed by 
Dr.AI.J. Brain, a British Anaesthesiologist, at London Hospital in 
1981. The use of a prototype was first described in 1983. Although a 
number of airway devices similar to laryngeal mask airway were 
described previously, none gained the popularity of the laryngeal mask 
airway. 
 It was Dr. Brain’s belief that the two methods by which the 
anatomical airway was commonly connected to an artificial airway were 
less than ideal. The most elegant way to join the two involves an end-to-
end junction at the glottis. The facemask falls short, because it forms the 
connection at the mouth and the nares and the endotracheal tube goes too 
far, penetrating the lumen of the respiratory tree. 
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 Many published trials have demonstrated the superiority of the 
laryngeal mask airway over endotracheal tube. 
  Despite the popularity of LMA for airway maintenance during 
general anaesthesia, there is still no optimal induction technique that 
guarantees good insertion conditions while maintaining cardiovascular 
stability and rapid onset of respiration. There have been numerous papers 
that looked into coinduction techniques combining a low  dose of 
propofol or thiopentone or with other agents, including benzodiazepines, 
rapidly acting opiates, neuromuscular blocking agents and topical or  
intravenous local  anaesthetic agents. 
 HO KM, Chui PT, (1999) 23  – studied the use of minidose suxame 
-thonium to facilitate the insertion of laryngeal mask airway. They 
divided the patients into two groups. After administration of intravenous 
propofol 2.5mg/kg. Group I received 0.9% sodium chloride and group II 
received succinylcholine 0.1mg/kg. They concluded that minidose 
suxamethonium improved correct positioning of LMA in first attempt, 
decreased the incidence of swallowing, gagging and head and limb 
movements. LMA insertion was graded as easy in 93% of patients who 
had mini-dose suxamethonium, compared with 60% in Group I. The total 
dose of propofol needed to insert the LMA was lower is Group II 
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 Yoshini A, HashimotoY, Hiroshima J, T. Hakoda et al (1999) 24 
compared the effects of low doses of succinylcholine in facilitating easy 
insertion of LMA during thiopentone anaesthesia. They divided the 
patients into three groups, Group I is control group – received normal 
saline, Group II received succinylcholine 0.25mg/kg, and Group III 
received succinylcholine 0.5 mg/kg. All group of patients received 
thiopentone as the induction agent. They concluded that insertion 
condition was good in patients who received succinylcholine 0.5 mg/kg. 
They also stated that adverse effects like coughing, gagging are reduced 
in succinylcholine group. They detected significant difference between 
group 3 and group 2 in the duration of apnoea. 
Christine JC Cheng, Sitaram Raman, Timothy, Chui Ping et al (2003) 
 Studied the effects of low dose succinylcholine for insertion of 
laryngeal mask airway following etomidate anaesthesia. They divided 
the patients into three groups. Group I received etomidate and normal 
saline, group II received etomidate and succinylcholine 0.25 mg/kg, 
Group III received succinylcholine 0.5mg/kg... In their study they stated 
that administration of succinylcholine increased the success rate of LMA 
insertion compared to the control group. 
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PTchui and E.M.W. Chearm 12 studied the use of low dose 
mivacurium to facilitate easy insertion of LMA following propofol 
induction. In their study, insertion was graded easy in 88% of patients 
who had received mivacurium compared to 50% of patients who received 
propofol alone. They concluded that low dose mivacurium facilitates 
laryngeal mask airway insertion and decreases the incidence of 
postoperative sore throat . 
Yaddanapudi et al and his colleagues found that thiopentone 3-
6mg/kg and suxamethonium 1.5mg/kg resulted in only one difficult 
insertion in 20 subjects. Based on these results, Yaddanapudi’s group 
suggested that insertion of LMA under neuromuscular block was an 
viable alternative to insertion with propofol and might be considered 
when the requirements of surgery necessitates controlled ventilation. 
Koh, Kwong Fah, Cheong, Kengfatt (1999) 25 studied  laryngeal 
mask insertion conditions using thiopental and low dose atracurium: a 
comparison with propofol. 120 patients were divided into 4 groups. 
Group I received 1 µg / kg fentanyl + 2.5 mg/kg propofol,group-2-
1μg/kgfentanyl+5mg/kg thiopentone group III – 1 µg/kg fentanyl + 5 
mg/kg Thio+ 0.05 mg/kg atacurium,Group-4-1μg/kgfentanyl+5mg/kg 
thiopentone+0.1mg/kg atracurium. They concluded that the combination 
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of thiopental-fentanyl with low dose atracurium (0.05 or 0.1mg/kg) 
provided conditions comparable with those of propofol for laryngeal 
mask insertion.  
 Naguib M, Samakandi AH – Studied the efficacy of low dose of 
rocuronium to facilitate laryngeal mask airway insertion following 
propofol anaesthesia. They observed that LMA insertion was graded easy 
in 90.6% of patients who received rocuronium compared to 42% of 
patients who received propofol alone. They concluded that rocuronium 
improved the overall insertion conditions and the optimal dose needed 
appeared to be 100 micrograms / kg. 
 Wong Punkamol, Boon Song P, Paiboon et al compared the two 
anaesthetic techniques for laryngeal mask airway insertion. In their 
study 60 patients were randomly allocated to receive either propofol 
2mg/kg or thiopentone 5mg/kg with succinylcholine 1.5mg/kg. They 
observed that mean insertion time was 8 sec and 5.5 sec respectively. 
63% of patients in propofol group experienced undesirable responses 
during insertion, while no patients in the thiopentone and succinylcholine 
group had adverse effects. 
 Nimmo SM; MC Cann N; Broome I.J.; Robb H.M. et al (1995) 27  
studied the effectiveness and sequlae of very low dose suxamethonium 
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for nasal intubation. Patients requiring nasal intubation were induced with 
propofol and alfentanil. 3 groups of 20 patients received nosuxa, suxa 
0.25mg/kg, suxa 0.5mg/kg. All patients received i.v. Fentanyl and 
diclofenac 100mg rectally for analgesia. Good intubating condition were 
produced in all 20 patients receiving suxa 0.25mg/kg, in 19 patients 
receiving suxa 0.5mg/kg and 11 patients not receiving neuromuscular 
blocking agents. The incidence of postoperative myalgia after suxa 
0.25mg/kg (20%) was not significant. 
 Chear EW, Chu PT 12 had done randomized double-blinded 
comparison of fentanyl, mivacurium or placebo to facilitate LMA 
insertion. The conclusion was fentanyl and mivacurium was equally 
effective in insertion of LMA following propofol anaesthesia. 
 Lee MP, Kua JA, Chin WK studied the use of remifentanyl for 
insertion of LMA. They concluded that remifentanyl 0.25 micrograms / 
kg when administrated after intravenous propofol 2.0mg/kg. provided 
excellent conditions for insertion of laryngeal mask airway with 
minimal hemodynamic disturbances. 
 Chiu CL, Wang CY, Chan YK et al (2005). In their study they 
evaluated the effectiveness on hemodynamics and insertion condition for 
laryngeal mask airway using ketamine – propofol, fentanyl – propofol 
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and propofol – saline. They concluded that the addition of ketamine 
0.5mg/kg improves haemodynamics when compared to fentanyl 1µg/kg, 
with less prolonged apnoea and is associated with better LMA insertion. 
 Seavell CR, Cook TM et al (1996) 26 They assessed conditions for 
insertion of a laryngeal mask airway in patients who received either 
thiopentone 5mg/kg preceded by 40mg of topical lignocaine to the 
posterior pharyngeal wall or propofol 2.5mg/kg alone. They concluded 
that thiopentone preceded by topical lignocaine spray provided conditions 
for insertion of a LMA equal to those of propofol, with more 
hemodynamic stability and a shorter period of apnoea. Gagging, 
coughing and laryngospasm following LMA insertion were graded and 
hemodynamic data and apnoea times were recorded. 
Bapat Pramod, Joshi Ravindra, Young Edward (1996) 19 assessed 
the ease of insertion of LMA with propofol versus thiopentone + 
midazolam / lidocaine. 150 patients were recruited into 3 groups. 
Anaesthetic induction was achieved with 1µg / kg Fentanyl i v followed 
by 2.5mg/kg – propofol – group P 
1.5mg/kg lidocaine + 5mg/kg thiopentone GPLT 
0.1mg/kg midazolam, 3mts later – 5mg/kg Thiopentone – GPMT 
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 They concluded that Thiopentone –Midazolam combination 
provided conditions as comparable with those of propofol. 
 Ti Liankah, Chow mark Y.H., Lee Tat, Leang et al (1999) 
compared the insertion conditions following propofol 3mg/kg and 
sevoflurane 8% single VCB induction. 
They concluded that single VCB induction with sevoflurane 
compares favorably with I.V. propofol induction for LMA insertion. 
However prolonged jaw tightness after the sevoflurane induction may 
delay LMA insertion. 
Tagaito, Yugo, Isono, Shiroh, Nishino, Takashi et al, (1998) 
studied on upper airway reflexes during a combination of propofol and 
fentanyl anaesthesia. They concluded that vigorous airway reflexes are 
elicited by laryngeal stimulation in patients anaesthetized with propofol 
alone. Although in general, incremental doses of fentanyl depress the 
airway reflex response in a dose related manner, a small dose of fentanyl 
does not effectively prevent laryngospasm.  
Brown GWL, Patel N, Ellis (1991) 9 compared the conditions for 
LMA insertion following induction with either thiopentone or propofol. 
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They concluded that thiopentone resulted in more incidence of gagging, 
coughing compared to propofol. 
Scan Lon, Carey M, Power M, Kirby F (1993) 8 compared the 
patient response to LMA insertion following induction with thiopentone 
or propofol. They stated that thiopentone alone was associated with 
greater incidence of gagging, coughing and head and limb movements. 
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MATERIALS AND METHODS 
 
After obtaining institutional ethical committee clearance and the 
patient consent, the study was carried out on 75 patients posted for 
elective surgical procedures lasting less than or equal to 45 min at Madras 
Medical College & GGH, Chennai. 
 Patients belonging to the age group of 18 – 50 years of both the 
sexes were selected. 
Inclusion Criteria 
- Elective short surgical procedures lasting less than or equal to 45 
min Patients of ASA physical status I and II 
- Aged between 18 – 50 years of both sexes. 
Exclusion Criteria 
- Patients with full stomach ,pregnant patient 
- Patients posted for emergency surgery  
- Patients with oral, peri oral pathology such as tumours, abscess or 
grossly enlarged tonsils 
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- Patients with fixed reduced pulmonary compliance such as 
pulmonary fibrosis, severe cardiovascular, hepatic or renal disease 
Types of Surgeries 
 The various types of surface surgeries that were included in this 
study are shown in table                           
Type of Surgeries  GroupA GroupB GroupC TOTAL
Fibroadenoma Excision 6 5 8 19 
Lipoma Excision 4 4 3 11 
Hydrocele – Excision and 
Eversion 
2 2 3 7 
Hernioraphy 3 2 2 7 
Ganglion excision 3 2 1 6 
Gynaecomastia – Webster’s 
Procedure 
1 1 1 3 
 Haemorrhoids,fissure in 
ano 
3 3 3 9 
Other minor surgeries 3 6 4 13 
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PATIENT PREPARATION: All patients were advised overnight 
fasting 
PRE-LOADING: All patients are preloaded with 10ml/kg of balanced 
salt solution. 
PRE MEDICATION: All patients were premedicated with  
 Inj. Glycopyrrolate 4mcg/kg i.v 
 Inj.fentanyl 2mcg/kg 
MONITORS USED: Non invasive Blood Pressure (NIBP), 
Electrocardiogram (ECG), Pulse oximetry. 
METHODOLOGY 
 All patients were randomly grouped under 3 groups viz., Group A 
propofol only, Group B propofol with midazolam, Group C propofol with 
succinylcholine . 
All patients are pre oxygenated with 100% O2 for 3 min. All 
patients are then   induced with propofol bolus until the endpoint of loss 
of eye lash reflex is obtained.Then in group C alone 0.1mg/kg succinyl 
choline  is  injected . We wait for 60 sec for fasciculations if any and 
proceed with LMA insertion. . Patients were then maintained on assisted 
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ventilation with 100% oxygen over a period of 60 secs.. After 60 sec, 
well-lubricated LMA was inserted by the standard techniques described 
in the intravent manual29. During insertion of laryngeal mask airway 
jaw relaxation, gagging / coughing, heads& limb movements, presence or 
absence of laryngospasm were noted. If jaw relaxation was found to be 
inadequate to permit LMA insertion, boluses of propofol were given until 
adequate jaw relaxation occurred. 
Jaw Relaxation  : Was graded by Young, Clark, Dundee  55 
Adequate - Adequate jaw relaxation with LMA insertion done 
without any difficulty  
Incomplete - Inadequate Jaw relaxation but LMA insertion is  
possible with difficulty  
Poor - Inadequate jaw relaxation and LMA insertion is not 
possible 
 
Overall Insertion Conditions : Was graded by Lund and Stovner 56 
Excellent - (Insertion – easy, no reaction from the patient) 
Good - (Insertion results in slight cough or movements ) 
 49
Poor 
 
Un acceptable 
- (Insertion possible but with marked patient 
response) 
Gagging or Coughing on Insertion : Was graded as  
Present  or  absent 
Head and Limb Movements :   Was graded as  
present  or  absent  
After insertion of LMA, Cuff was inflated with appropriate volume 
of air and connected to the breathing circuit. Correct positioning of the  
LMA was verified by bilateral  chest expansion, bilateral air entry by 
auscultation, capnography and the absence of leak around the cuff. The 
Ventilation was assisted with bag until resumption of spontaneous 
respiration. Anaesthesia was maintained with oxygen (2lt/ min), Nitrous 
oxide (4l/ min) and Halothane (1-2%). The hemodynamics were 
monitored  before premedication, 1 minute prior to induction, 30 sec after 
induction and 1 minute after LMA insertion and throughout the 
procedure. At the end of surgery all the anaesthetic agents were 
discontinued and 100% oxygen administered. LMA was removed after 
the patient had gained adequate level of consciousness and after adequate 
return of pharyngeal reflexes. After removal of LMA, the patient was 
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observed for any spasm, coughing, vomiting. In the postoperative period, 
the patients were observed in the ward for 24 hours. 
STATISTICAL ANALYSIS USING STUDENT T TEST 
The t-test assesses whether the means of two groups are 
statistically different from each  other. The t-value will be positive if the 
first mean is larger than the second and negative  if it is smaller. Once we 
compute the t-value we look it up in a table of significance to  test 
whether the ratio is large enough to say that the difference between the 
groups is not  likely to have been a chance finding. 
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OBSERVATIONS AND RESULTS 
This study was conducted on 75 patients who were divided into 3 
groups of   25 patients each. 
Group A - Propofol Group 
 
Group B - Propofol with midazolam group 
 
Group C -  Propofol with succinyl choline group 
Demographic Profile 
In group A and C, 48% of patients are males and rest 52% are 
females, while in group B 52% of patients are males and rest females. 
The mean age of patient is 30.52, 30.12 and 30.84 in groups A, B and C 
respectively. The mean weight is 51.8, 53 and 53.22 in groups A, B and C 
respectively. Patients in each group were statistically comparable  in 
relation to sex, age and weight. See Fig-2 & 3.  
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Comparison of conditions for LMA insertion 
 Jaw relaxation, overall insertion conditions and number of attempts 
for LMA insertion were observed and the results were tabulated as 
follows. Also see figure 4 
Jaw Relaxation Group A Group B Group C 
Adequate  8 25 16 
Incomplete 17 0 9 
Poor 0 0 0 
 
One-Sample Statistics 
 
 N Mean Std. Deviation Std. Error Mean 
Adequate 3 16.33 8.505 4.910 
Incomplete 3 8.67 8.505 4.910 
 
 
 One-Sample Test 
 
 
Test Value = 0 
t df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Adequate 3.326 2 .080 16.333 -4.79 37.46 
Incomplete 1.765 2 .220 8.667 -12.46 29.79 
 
Jaw relaxation was more in group B compared to groups A or C, 
and the results are statistically significant as shown in tables above. 
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Overall  Ease Of Insertion 
The overall ease of insertion is graded as excellent, good, poor or 
unacceptable. The overall ease of insertion is excellent in 32% of group A 
patients, while it is 100% in group B and 44% in group C . See Fig.5. 
Ease of insertion Group A Group B Group C 
Excellent 8 25 11 
Good 17 0 14 
Poor 0 0 0 
 
 
 
One-Sample Statistics 
 
  N Mean Std. Deviation 
Std. Error 
Mean 
Excellent 3 14.67 9.074 5.239
Good 3 10.33 9.074 5.239
Poor 3 .00 .000(a) .000
a  t cannot be computed because the standard deviation is 0. 
 
 
One-Sample Test 
 
  
Test Value = 0 
t df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Excellent 2.800 2 .107 14.667 -7.87 37.21
Good 1.972 2 .187 10.333 -12.21 32.87
 
 
The overall insertion conditions are excellent in Group B  
(Propofol with Midazolam) compared to the other groups  and 
this is statistically significant as shown above. 
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NUMBER OF ATTEMPTS FOR SUCCESSFUL INSERTION OF LMA 
In 100% of patients in group B , LMA was inserted in the first 
attempt, while  in only 40 % and 64% of patients in groups A and C 
respectively LMA was inserted in the first attempt. This is represented as 
the following data. See Fig.6. 
Attempts Group A Group B Group C 
First attempt 10 25 16 
Second attempt 15 0 9 
 
   
One-Sample Statistics 
 
  N Mean Std. Deviation 
Std. Error 
Mean 
FirstAttempt 3 17.00 7.550 4.359
SecondAttempt 3 8.00 7.550 4.359
 
 
One-Sample Test 
 
  Test Value = 0 
  
  
t df Sig. (2-tailed) 
Mean 
Differen
ce 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
First Attempt 3.900 2 .060 17.000 -1.75 35.75
Second Attempt 1.835 2 .208 8.000 -10.75 26.75
 
 
100% of  LMA insertions in Group B was done in the first attempt  
while  Only 40%  and  64%  of  LMA insertions were done in the first 
attempt in  Groups A and C respectively, this is statistically significant as 
shown above. 
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 COMPARISON OF PATIENT RESPONSE TO LMA INSERTION  
 Patient movement,  gagging ,coughing, laryngospasm during LMA 
insertion were compared between the 3 groups. See Fig.7. 
Patient Movement 
Pt moving Group A Group B Group C 
YES 12 0 3 
NO 13 25 22 
 
 
One-Sample Statistics 
 
  N Mean Std. Deviation 
Std. Error 
Mean 
Yes 3 5.00 6.245 3.606 
No 3 20.00 6.245 3.606 
 
 
One-Sample Test 
 
  
Test Value = 0 
t Df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Yes 1.387 2 .300 5.000 -10.51 20.51
No 5.547 2 .031 20.000 4.49 35.51
 
 
There was no patient movement in all patients of group B, 
whereas there was movement in 48% of patients in group A and  
12% of  patients in group C, which is statistically very 
significant. Additional doses of propofol was used for those 
patients. 
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Laryngospasm 
 GROUPA GROUP B GROUP C 
YES 0 0 0 
NO 25 25 25 
 
In both the groups, there was no incidence of laryngospasm. Likewise 
there was no gagging or coughing in all 3 groups. 
Total dose of propofol (mg/kg) required for LMA insertion 
 Group A  Group B Group C 
Total Propofol 
dose(mg/kg) 2.76 2.06 2.60 
 
One-Sample Statistics 
 
  N Mean Std. Deviation 
Std. Error 
Mean 
Dose 3 2.4733 .36679 .21177 
 
 
  
One-Sample Test 
 
  
Test Value = 0
t Df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Dose 11.680 2 .007 2.47333 1.5622 3.3845
 
 
The  mean total doses of propofol used  are  2.76, 2.06, and 2.60  
respectively in groups A, B, C. Group-B patients required lesser dose of 
propofol than Group A&C patients which is also statistically significant.  
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Airway Trauma     
 
Airway trauma Group A Group B Group C 
Yes 9 0 9 
No 16 25 17 
 
Also see fig. 8 
 
One-Sample Statistics 
 
Airway 
trauma N Mean Std. Deviation 
Std. Error 
Mean 
Yes 3 5.67 4.933 2.848 
No 3 19.33 4.933 2.848 
 
 
One-Sample Test 
 
Airway 
trauma 
Test Value = 0 
t df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
YEs 1.990 2 .185 5.667 -6.59 17.92
TNo 6.788 2 .021 19.333 7.08 31.59
  
The incidence of airway trauma as witnessed by blood staining of 
LMA is 36% in group A and 32%  in group C, while  none of group B  
had  any, which is statistically significant 
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HEMODYNAMIC CHANGES -PULSE RATE AND MAP 
The mean variability in heart rate (heart rate pre op minus heart 
rate 1min Post insertion) is least in group B which is statistically 
significant. The pictoral representation of the mean variability in heart 
rate (pre op heart rate minus 1min post insertion heart rate) is as follows. 
Also see Fig.9&10 
 
One-Sample Statistics 
 
 N Mean Std. Deviation Std. Error Mean 
HR 3 19.28 2.383 1.376 
 
 
One-Sample Test 
 
  
Test Value = 0 
t Df Sig. (2-tailed) 
Mean 
Difference
95% Confidence 
Interval of the 
Difference 
Lower Upper 
HR 14.014 2 .005 19.280 13.36 25.20
 
 
The  mean variability in mean arterial pressure (pre op MAP minus 
1min post insertion MAP ) is least in case of group B patients than groups 
A or C, which is statistically significant. There is no change in saturation 
(SPO2) levels either preop, post induction or post insertion between the 3 
groups.  
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One-Sample Statistics 
 
  N Mean Std. Deviation 
Std. Error 
Mean 
MAP 3 21.28 1.698 .980 
 
 
One-Sample Test 
 
  Test Value = 0 
  
  
t 
  
Df 
  
Sig. (2-
tailed) 
  
Mean 
Difference
  
95% Confidence 
Interval of the 
Difference 
Lower Upper 
MAP 21.713 2 .002 21.280 17.06 25.50 
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DISCUSSION 
 Adverse responses to insertion of laryngeal mask airway such as 
gagging, coughing and laryngospasm, may make correct positioning 
difficult or even impossible. So LMA insertion requires suppression of 
upper airway reflexes. Although Propofol obtunds the upper airway 
reflexes, Stoneham, Bree and sneyd reported that easy insertion of the 
LMA was seen in only approximately 62% of patients with Propofol 
anaesthesia10, which means that the sole use of Propofol does not always 
guarantee successful insertion of LMA comparisons have been made 
between various muscles relaxants in the LMA insertion. 
Wafaa Taha Salem, Dept of Anesthesiology, National Cancer 
Institute, Cairo University investigated the use of  Midazolam or mini 
dose Succinyl choline as a co induction agent with Propofol to facilitate 
LMA Insertion in 60 patients undergoing urological procedures. The 
patients were Divided into 3 groups ; Propofol  group(P)  receiving  
2.5mg/kg Propofol for Induction, while group PM received 0.04 mg/kg 
Midazolam 3 min pre induction and group PS received 0.1mg/kg succinyl 
choline 30sec after propofol. The number of insertion attempts, total dose 
of  Propofol, jaw relaxation, gagging, coughing, patient movement, 
laryngospasm, overall insertion conditions and hemodynamic changes 
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were recorded. Significant reduction in induction  dose of propofol was 
noted in PM group(40%).The success rate at first attempt was 60%, 95% 
and 90% in P, PM and PS group respectively. The overall insertion 
conditions was excellent in 20%, 75% and 50% respectively in the 3 
groups. Group PM showed less hemodynamic change. The incidence of 
fasciculation and myalgia was 20% in group PS. The study showed that 
Midazolam had the advantage of reducing the dose of propofol and 
producing hemodynamic stability. 
 In our study also, the total dose of Propofol was low by 25% in 
group B compared to group A,the ease of insertion was graded excellent 
in 100% of patients in group B compared to 32% and 44% in groups A 
and C  respectively. Jaw relaxation was adequate in all patients of group 
B while it was only 32% and 64% in groups A and C respectively.LMA 
was inserted in first attempt in all group B cases while in 40% and 64% 
of group A and C, it was inserted in first attempt. Also group B patients 
were more hemodynamically stable than the rest of the patients. Hence it 
is concluded that Midazolam  aids LMA insertion in Propofol anesthesia 
for LMA insertion. 
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 A randomized, double blind, placebo control study conducted at 
Maisonneuve-Rosemont Hospital in july,2008  investigated the effects of 
fentanyl-midazolam  premedication during sevoflurane anesthesia for 
proseal LMA insertion in adult elective surgery patients. Two groups of 
40 patients each were given either NaCl( placebo) or fentanyl0.6 
mcg/kg+ midazolam 9 mcg/kg 5 min before tidal volume sevoflurane 8% 
induction with 6 L/ min O2. Hemodynamics  at end of induction and 
1min, 5min post insertion were recorded and plotted against pre op 
values. The number of insertion attempts,jaw relaxation, gagging, 
coughing, patient movement, laryngospasm,overall linsertion conditions  
were recorded. It was found that  fentanyl-midazolam  group had stable 
hemodynamics, 95% first attempt insertion rate compared to 72% in 
placebo group and excellent insertion conditions with no gagging, 
coughing, movement or laryngospasm compared to placebo group. 
 In our study, fentanyl is common to all 3 groups. In group B  
(Midazolam) the jaw relaxation and overall ease of insertion were far 
better (100% in group B to 32% and 64% in groups A and C 
respectively.)The number of cases in which LMA was inserted in first 
attempt was also 100% compared to 40% and  64% respectively in groups 
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A and C. Hemodynamics were also stable in group B compared to groups 
A  and C. 
 A prospective, randomized, double-blind, controlled study was 
conducted in 60 ASA 1,2 subjects. Normal  saline,  ketamine 0.5mg/kg, 
midazolam 0.05mg/kg  were administered in groups P(propofol), PK 
(propofol-ketamine) and PM (propofol –midazolam), respectively 2 min 
prior to the administration of the induction dose of propofol. Propofol 
3.5mg/kg (group P) or 2.5mg/kg (groups PK and PM) was used for 
induction, LMA inserted 30sec later and insertion conditions assessed. 
Heart rate and blood pressure were recorded immediately after propofol 
bolus, then every min till 2min after LMA insertion. In group P ,systolic 
blood pressure (SBP) showed a significantly greater decrease compared 
to group PK and PM .Only 5% of patients in group PK and PM showed > 
20% fall in SBP compared to 89% in group P . 
  In our study also group B (midazolam group) patients were more 
hemodynamically stable than the rest of the patients. Hence it is 
concluded that midazolam  aids LMA insertion in propofol anesthesia for 
LMA insertion. 
 Hokm and PT Chui studied the use of minidose succinyl choline 
for LMA insertion. They concluded that suxamethonium improved 
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correct positioning and insertion in first attempt. They also observed that 
the total dose of propofol needed to insert LMA was lower in 
succinylcholine group and was associated with less hypotension 
 In our study also, in 64% of cases in group C LMA was inserted in 
the first attempt which is more than in group A(40%)  but less than in 
group B (100%). Also  only 2.60 mg/kg of propofol was  needed in group 
C compared to 2.76mg/kg in A group,(although it is only 2.06mg/kg in 
group B). 
       Cook TM, Seavel et al, compared topical and intravenous 
lignocaine to aid insertion of LMA with thiopentone. The group who had 
lignocaine topical had a lower incidence of laryngospasm. 
 In the present study there was no incidence of laryngospasm in 
both the groups 
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SUMMARY 
In this study, the conditions of LMA insertion, patient’s response 
to LMA insertion and the hemodynamic changes during and after LMA 
insertion in the following three groups of patients were observed. 
 Group A - Inj. Propofol 2.5mg/kg only  
 Group B - Inj. Propofol 2.5 mg/kg + 0.04mg/kg midazolam 
            Group C- Inj. Propofol 2.5 mg/kg + 0.1 mg/kg succinyl choline 
• The jaw relaxation was adequate in 100% of group B patients 
compared to 32 % of patients in group A and 64% in group C. 
• Overall insertion conditions were excellent in 100% of patients in 
Group B compared to 32% in Group A and 44% in group C. 
• LMA was inserted successfully in the first attempt in 100% of 
patients in Group A compared to 40% in Group A and 64% in 
group C. 
• Airway trauma as evidenced by blood staining of LMA was found 
in 36% of patients in group A and 32% in group C while none of 
the patients in group B had any airway trauma. 
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• Post op myalgia was present in 40% of patients in group C. 
• Patient movements were present in 48% of patients in Group A   
compared to 12% in Group C while no movement was present in 
any of the patient in group B 
• The total dose of Propofol required for successful insertion of 
LMA was 2.76mg/kg in Group A and 2.60 mg/kg in Group 
C,while it is the least 2.06mg/kg in group B which is the cause of 
significant hemodynamic stability in patients of group B 
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CONCLUSION 
To conclude, addition of Midazolam (0.04mg/kg) to the standard 
dose of propofol provides better LMA insertion conditions than the 
addition of mini-dose Succinyl Choline (0.1mg/kg). 
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FIG-9 
HEMODYNAMIC CHANGES- HEART RATE 
 
FIG-8 
AIRWAY TRAUMA 
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FIG-7 
PATIENT MOVEMENT 
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FIG-6 
NUMBER OF ATTEMPTS 
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FIG-5 
OVERALL EASE OF INSERTION 
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FIG –2 
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FIG-3 
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 PROFORMA 
Name: 
Age   :                 Sex  :        IPno:          wt(Kgs):                             
Diagnosis:                                                                         
Plan:                                                                             
Preop assessment : 
History of any comorbid illness or allergy: 
 
 
 
 
BP:                                                CVS: 
PR:                                                 RS: 
SPO2   
 
 
Premed:                            inj.glyco          fentanyl 
  4 microgram/kg           2microgram/kg 
                                                  
Dose :  __________   __________ 
 
    Inj.midaz(if applicable)    inj succinylcholine 
       (if applicable) 
                                               0.04 mg/kg                        0.1mg/kg 
 
Dose :  __________   __________ 
 
 
Propofol:            Induction                  ---------------(2.5mg/kg) 
    
   
Supplemental dose ---------(0.25mg/kg) once in 15 sec 
               
---------(0.25mg/kg) 
 
---------(0.25mg/kg) 
 
 Total dose  ---------mgs( -------- in mg/kg) 
 
Group : 
 OUTCOME MEASURES (tick appropriate) 
 
     Yes              No 
 1. Gagging  
 2. Coughing 
 3. Patient movement 
 4. Laryngospasm 
 
     Adequate      Incomplete         Poor 
5. Jaw relaxation 
 
            Excellent    Good      Poor    Unacceptable 
 
 6. Overall insertion ease 
 
 
SECONDARY OUTCOME MEASURES  
 
1. Number of attempts 
2.  Duration of insertion (from induction to conformation of 
placement) 
3. Airway trauma (blood staining of LMA )     yes/no 
Pre op                Post induction               Post insertion 
                          1.min        5.min 
4. BP      Sys 
  Dias 
 
5. PR 
 
6. Spo2   
 
  
DATE: 
TIME: 
THEATRE: 
 
SIGNATURE OF GUIDE     SIGNATURE OF STUDENT 
MASTER CHART
S.
No Age SEX IP.No SURGERY
Wt
(Kgs) GROUP GAGGING COUGHING
PATIENT 
MOVEME
NTS
LARYNG
O 
SPASM
JAW 
RELAXATIO
N
EASE OF 
INSERTI
ON
TOTAL 
PROPOF
OL
(mg/kg)
No Of 
ATTEMP
T
AIRWAY 
TRAUMA
HEART RATE\Min
PRE OP(1)    POST INDUCTION (2)     POST INSERTION(1min)(3)
1 15 M 32116 R Hernioraphy 53 A NO NO YES NO Incomplete Good 3.00 2 NO       102                            90                                            80 
2 30 F 28114 L Fibroadenoma Excision 48 A NO NO YES NO Incomplete Good 3.00 2 YES         98                             82                                           74
3 34 M 29118 L Eversion Of Sac 64 A NO NO YES NO Incomplete Good 3.00 2 YES       102                             84                                           80
4 22 M 21443 Circumscicion 55 A NO NO YES NO Adequate Excellent 2.75 2 NO      100                              90                                           84
5 24 F 31446 R Fibroadenoma Excision 49 A NO NO NO NO Adequate Excellent 2.50 1 NO        98                              88                                           80
6 48 F 11916 Hemorrhoidectomy 62 A NO NO YES NO Incomplete Good 2.75 2 YES        98                              84                                           80
7 17 M 31094 R websters 50 A NO NO YES NO Incomplete Good 3.00 2 NO        92                              74                                           70
8 19 F 31001 L Fibroadenoma Excision 44 A NO NO NO NO Adequate Excellent 2.50 1 NO        90                              72                                           70
9 37 F 29142 L Cervical Node Biopsy 51 A NO NO NO NO Adequate Excellent 2.50 1 YES        94                              84                                           80
10 46 M 19442 L Varicocelectomy 4O A NO NO NO NO Incomplete Good 2.75 2 NO        98                              82                                           80
11 23 M 28414 Lipoma L thigh excision 52 A NO NO YES NO Incomplete Good 2.75 1 NO        94                              94                                           68
12 18 F 31098 Ganglion R Hand 42 A NO NO NO NO Adequate Excellent 2.50 1 NO        98                              84                                           80
13 36 M 31719 Lat Spincterotomy 64 A NO NO NO NO Adequate Excellent 2.50 1 YES        94                              80                                           74
14 29 F 32408 Fibroma R Thigh 56 A NO NO NO NO Adequate Excellent 2.50 2 NO      104                             88                                            82
15 30 M 32499 L Hernioraphy 50 A NO NO NO NO Incomplete Good 2.75 2 NO        98                              90                                           84
16 41 M 91426 Lipoma Axilla Excision 46 A NO NO YES NO Incomplete Good 3.00 2 YES        94                              90                                           74
17 16 M 38904 L Ant Chestwall Lip Excision 50 A NO NO NO NO Incomplete Good 2.75 2 NO      100                              90                                           74
18 20 F 38094 R Fibroadenoma Excision 52 A NO NO YES NO Incomplete Good 2.75 1 NO        98                              90                                            72
19 32 M 31168 L Hernioraphy 62 A NO NO NO NO Incomplete Good 2.50 2 YES      108                              92                                            82
20 42 F 41913 Sec Suturing 56 A NO NO YES NO Incomplete Good 2.75 1 NO         98                             78                                            64
21 47 F 31816 Ganglion L Hand Excision 58 A NO NO NO NO Adequate Excellent 2.50 2 NO         94                             84                                            80
22 26 F 31411 L Fibroadenoma Excision 60 A NO NO YES NO Incomplete Good 3.00 2 NO       100                            84                                            70
23 27 F 32410 Lat Sphincterotomy 61 A NO NO NO NO Incomplete Good 3.00 2 YES         98                            88                                             80
24 45 M 41901 L Eversion Of Sac 53 A NO NO YES NO Incomplete Good 3.50 1 YES         98                            80                                             64
25 39 F 38104 L Phylloids Excision 57 A NO NO NO NO Incomplete Good 2.50 1 NO       100                            90                                             72
26 39 M 30517 Lat Sphincterotomy 62 B NO NO NO NO Adequate Excellent 2.00 1 NO          92                            88                                            82 
27 17 F 30846 R Fibroadenoma Excision 45 B NO NO NO NO Adequate Excellent 2.00 1 NO        100                            92                                            90
28 50 F 26899 Sinus tract Exploration 50 B NO NO NO NO Adequate Excellent 2.00 1 NO          88                            80                                            74
29 28 F 27872 R Fibroadenoma Excision 50 B NO NO NO NO Adequate Excellent 2.00 1 NO        102                            90                                            84
30 19 M 31194 L Websters 55 B NO NO NO NO Adequate Excellent 2.00 1 NO          92                            82                                            70
31 44 M 32132 Lipoma Excision 65 B NO NO NO NO Adequate Excellent 2.00 1 NO        110                            92                                            82
32 18 M 32779 R websters 45 B NO NO NO NO Adequate Excellent 2.00 1 NO          94                             88                                            82
33 16 M 33512 L Herniotomy 35 B NO NO NO NO Adequate Excellent 2.50 1 NO          94                             82                                            62
34 27 M 23416 R Thigh Fibroma Excision 53 B NO NO NO NO Adequate Excellent 2.50 1 NO          99                             86                                            80
35 36 M 21416 Lat Sphincterotomy 60 B NO NO NO NO Adequate Excellent 2.00 1 NO        106                             94                                            90
36 32 M 23937 Hemorrhoidectomy 44 B NO NO NO NO Adequate Excellent 2.00 1 NO          94                             82                                            84
37 22 M 21499 L Eversion Of Sac 50 B NO NO NO NO Adequate Excellent 2.00 1 NO          96                             90                                            80
38 26 M 33719 L Eversion Of Sac 65 B NO NO NO NO Adequate Excellent 2.00 1 NO          92                             84                                            68
39 42 F 28255 L Fibroadenoma Excision 58 B NO NO NO NO Adequate Excellent 2.00 1 NO        108                             92                                            90
40 21 F 36438 L Fibroadenoma Excision 50 B NO NO NO NO Adequate Excellent 2.00 1 NO        110                            103                                           97
41 23 F 26119 Ganglion Excision 60 B NO NO NO NO Adequate Excellent 2.50 1 NO          96                              90                                            80
42 26 M 26318 Varicocelectomy 56 B NO NO NO NO Adequate Excellent 2.00 1 NO          98                              80                                            72
S.
No Age SEX IP.No SURGERY
Wt
(Kgs) GROUP GAGGING COUGHING
PATIENT 
MOVEME
NTS
LARYNG
O 
SPASM
JAW 
RELAXATIO
N
EASE OF 
INSERTI
ON
TOTAL 
PROPOF
OL
(mg/kg)
No Of 
ATTEMP
T
AIRWAY 
TRAUMA
HEART RATE\Min
43 48 F 28807 L Fibroadenoma Excision 65 B NO NO NO NO Adequate Excellent 2.00 1 NO          92                              82                                            80
44 37 F 21441 Lipoma Excision Chestwall 55 B NO NO NO NO Adequate Excellent 2.00 1 NO        100                              92                                            80
45 34 F 23493 Naevus Face Excision 52 B NO NO NO NO Adequate Excellent 2.00 1 NO          89                              70                                            64
46 42 M 26443 R Dermoid Excision 48 B NO NO NO NO Adequate Excellent 2.00 1 NO          96                              88                                            84
47 31 F 27431 Tatoo Chest Excision 57 B NO NO NO NO Adequate Excellent 2.00 1 NO          93                              80                                            73
48 42 M 21916 R Hernioraphy 60 B NO NO NO NO Adequate Excellent 2.00 1 NO          94                              80                                            80
49 16 F 23415 Lypoma R Thigh Excision 40 B NO NO NO NO Adequate Excellent 2.00 1 NO          98                              88                                            80
50 17 F 22119 Sural Nerve Biopsy 45 B NO NO NO NO Adequate Excellent 2.00 1 NO        102                             94                                            90
51 38 F 30790 Lump Breast Excision 68 C NO NO NO NO Adequate Excellent 2.50 1 NO        120                           104                                            98 
52 18 F 30824 L Fibroadenoma Excision 45 C NO NO NO NO Adequate Good 2.75 2 NO        104                             86                                            80
53 32 M 33232 R Eversion Of Sac 60 C NO NO NO NO Adequate Excellent 2.50 1 NO          95                             82                                            76
54 19 F 36077 L Axilla Lipoma 48 C NO NO YES NO Incomplete Good 2.75 2 YES        102                             92                                            80
55 49 F 32359 R Phylloids Excision 45 C NO NO NO NO Incomplete Good 2.50 1 NO          89                             76                                            62
56 16 M 31414 Cervical Node Biopsy 45 C NO NO NO NO Incomplete Good 2.50 1 YES        100                             96                                            90
57 38 M 36083 L Hernioraphy 52 C NO NO NO NO Incomplete Good 2.50 1 YES          80                             76                                            74
58 43 F 32310 RBr Lump Excision Bx 55 C NO NO NO NO Incomplete Good 2.50 1 YES          92                             86                                            80
59 29 F 34290 R Fibroadenoma 40 C NO NO NO NO Adequate Good 2.75 2 YES          88                             80                                            78
60 25 F 34453 L Firoadenoma Excision 41 C NO NO NO NO Adequate Good 3.00 2 YES          98                             92                                            82
61 35 M 34448 L Eversion Of Sac 64 C NO NO NO NO Adequate Excellent 2.50 1 NO          86                             68                                            66
62 44 M 34435 Hemorrhoidectomy 55 C NO NO NO NO Adequate Good 2.50 1 YES          87                             78                                            74
63 28 F 34530 R Fibroadenoma Excision 62 C NO NO NO NO Adequate Excellent 2.50 1 NO          98                             90                                            88
64 42 M 34919 R Hernioraphy 56 C NO NO YES NO Incomplete Good 2.75 2 NO          94                             90                                            80
65 32 F 34937 L Chestwall Lipoma Excision 50 C NO NO NO NO Incomplete Good 2.50 1 NO          96                             92                                            80
66 37 F 34922 Ganglion Excision 48 C NO NO YES NO Incomplete Good 2.75 2 YES        102                             88                                            82
67 34 F 33914 Fibroma R Thigh Excision 54 C NO NO NO NO Adequate Excellent 2.50 1 NO          94                             80                                            70
68 41 F 32814 Sinus R Ing Region Excision 52 C NO NO NO NO Incomplete Good 2.75 2 NO          98                             88                                            76
69 46 M 30041 L Eversion Of Sac 60 C NO NO NO NO Adequate Excellent 2.50 1 NO        104                             90                                            84
70 17 F 31100 R Firoadenoma Excision 48 C NO NO NO NO Adequate Excellent 2.50 1 NO          96                              84                                           74
71 16 M 39403 Lat Sphincterotomy 49 C NO NO NO NO Adequate Excellent 2.75 2 NO          90                              78                                           74
72 19 M 38406 Sec Suturing region 52 C NO NO NO NO Adequate Excellent 2.50 1 NO          98                              84                                            82
73 22 M 38411 Lipoma Excision 55 C NO NO NO NO Adequate Good 2.75 2 NO          94                              82                                            74
74 24 M 37618 Sinus Exploration R Ing 50 C NO NO NO NO Adequate Excellent 2.50 1 NO        100                              92                                            88
75 27 M 31435 L Webster Operation 54 C NO NO NO NO Adequate Excellent 2.50 1 NO          98                               82                                            78
HEART 
RATE\
Min2
MAP MAP SATURATION SATU-RATION
(1-3) PRE OP(1)    POST INDUCTION (2)     POST INSERTION(1min)(3) (1-3) PRE OP(1)    POST INDUCTION (2)     POST INSERTION(1min)(3) (1-3)
22        96                                81                                           74 22       100                           100                                         100 0
24         92                               80                                           72 20       100                           100                                         100 0
22       100                               78                                           74 26       100                           100                                         100 0
16         98                               84                                            80 18       100                           100                                         100 0
18         92                               78                                            72 20       100                           100                                         100 0
18       102                               90                                            82 20       100                           100                                         100 0
22         94                               88                                            78 16       100                           100                                         100 0
20       101                               90                                            84 17       100                           100                                         100 0
14         98                               90                                            81 17       100                           100                                         100 0
18       100                               88                                           76 24       100                           100                                         100 0
26         98                              74                                            70 28       100                           100                                         100 0
18       100                              90                                            78 22       100                           100                                         100 0
20         98                              84                                            80 18       100                           100                                         100 0
22       101                              91                                             80 21       100                           100                                         100 0
14       102                              90                                             78 24       100                           100                                         100 0
20         92                              80                                             74 18       100                           100                                         100 0
26         98                              78                                             74 24       100                           100                                         100 0
26         94                              80                                             78 16       100                           100                                         100 0
26       101                              88                                             84 17       100                           100                                         100 0
34         92                              80                                             68 24       100                           100                                         100 0
14         90                              72                                             70 20       100                           100                                         100 0
30         98                              72                                             68 30       100                           100                                         100 0
18         98                              70                                             60 38       100                           100                                         100 0
34       100                              72                                             68 32       100                           100                                         100 0
28         98                              78                                             74 24       100                           100                                         100 0
10         99                               83                                            72 27       100                           100                                         100 0
10         90                               64                                            65 25       100                           100                                         100 0
14         96                               78                                            75 21       100                           100                                         100 0
18        83                                71                                            70 13       100                           100                                         100 0
22        94                                82                                            73 21       100                           100                                         100 0
28       105                               75                                            71 34       100                           100                                         100 0
12         91                               71                                            74 17       100                           100                                         100 0
32         90                               74                                            71 29       100                           100                                         100 0
19       102                               90                                            85 17       100                           100                                         100 0
16       106                               92                                            88 18       100                           100                                         100 0
10         92                               80                                             72 20       100                           100                                         100 0
16         90                               81                                             76 14       100                           100                                         100 0
24         96                               85                                             72 24       100                           100                                         100 0
18       100                              89                                              85 15       100                           100                                         100 0
13         93                               65                                             68 25       100                           100                                         100 0
16         90                               82                                             76 14       100                           100                                         100 0
26         90                               80                                             72 18       100                           100                                         100 0
HEART 
RATE\
Min2
MAP MAP SATURATION SATU-RATION
12         84                               70                                             73 11       100                           100                                         100 0
20         90                               72                                             72 18       100                           100                                         100 0
25         96                               78                                             68 28       100                           100                                         100 0
14         90                               81                                             77 13       100                           100                                         100 0
20         92                               80                                             76 16       100                           100                                         100 0
14         92                               80                                             78 14       100                           100                                         100 0
18         90                               82                                             72 18       100                           100                                         100 0
12         93                               81                                             80 13       100                           100                                         100 0
22        108                              96                                             86 22       100                           100                                         100 0
24         96                               80                                             76 20       100                           100                                         100 0
19       110                               85                                             73 37       100                           100                                         100 0
22       100                               76                                             70 30       100                           100                                         100 0
27         96                                85                                             67 29       100                           100                                         100 0
10         89                                76                                             69 20       100                           100                                         100 0
6       101                                88                                             86 15       100                           100                                         100 0
12       106                                85                                             80 26       100                           100                                         100 0
10         97                                81                                              72 25       100                           100                                         100 0
16         93                                79                                              78 15       100                           100                                         100 0
20         96                                79                                              76 20       100                           100                                         100 0
13         86                                65                                              66 20       100                           100                                         100 0
10       100                                90                                             75 25       100                           100                                         100 0
14         98                                80                                              70 28       100                           100                                         100 0
16       101                                81                                             74 27       100                           100                                         100 0
20       105                                90                                              85 20       100                           100                                         100 0
24         98                                82                                              76 22       100                           100                                         100 0
22       100                               88                                               82 18       100                           100                                         100 0
20       101                               92                                               86 15       100                           100                                         100 0
16         98                               88                                               78 20       100                           100                                         100 0
16         96                               76                                               72 24       100                           100                                         100 0
16         98                               84                                               80 18       100                           100                                         100 0
20         98                               86                                               76 22       100                           100                                         100 0
12       101                              88                                                82 19       101                           100                                         100 0
20          92                             80                                                72 20       102                           100                                         100 0
